SCHEMBL29889754

SCHEMBL29889754

COc1cc(OC)cc(Oc2ncccc2-c2cc(OC)cc(OC)c2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 3/20 0.50
TUBB P07437 3/20 0.50
TUBA3C P0DPH7 3/20 0.50
TUBA1B P68363 3/20 0.50
TUBA4A P68366 3/20 0.50
TUBB4B P68371 3/20 0.50
TUBB3 Q13509 3/20 0.50
TUBB2A Q13885 3/20 0.50
TUBB8 Q3ZCM7 3/20 0.50
TUBA3E Q6PEY2 3/20 0.50
TUBA1A Q71U36 3/20 0.50
TUBA1C Q9BQE3 3/20 0.50
TUBB6 Q9BUF5 3/20 0.50
TUBB2B Q9BVA1 3/20 0.50
TUBB1 Q9H4B7 3/20 0.50
ABL1 P00519 2/20 0.50
ABCB1 P08183 2/20 0.50
BCR P11274 2/20 0.50
PDE10A Q9Y233 2/20 0.46
DYRK1A Q13627 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29889799 0.90 MEN1 (0.51) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29889828 0.90 PDE10A (0.53) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29889769 0.86 PDE10A (0.49) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29889987 0.85 PDE10A (0.52) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29889768 0.85 PDE10A (0.55) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29889824 0.84 DYRK1A (0.52) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29890064 0.84 PDE10A (0.50) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29889745 0.81 PDE10A (0.46) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29890053 0.78 DRD1 (0.43) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL20394469 0.77 PDE10A (0.57) PDE10ADYRK1ACLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240262803-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS Chungdu Anticancer Bioscience Ltd (CN) 2024-08-08 US disclosed
WO-2022199654-A1 HETEROARYL-HETEROARYL-O-PHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER DISORDERS Chengdu Anticancer Bioscience, Ltd. (CN) 2022-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240262803-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CYP27A1, PNLIP, GOT2 TUBB4A 858/4885TUBB 771/4885TUBA3C 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.